ACC-001 + QS-21

BIOLOGICAL2 trials

Sponsors

Pfizer

Conditions

Alzheimer Disease

Phase 2

Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

CompletedNCT00479557

PfizerAlzheimer Disease

Start: 2007-05-31End: 2013-01-31Updated: 2016-01-01

Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease

CompletedNCT00498602

PfizerAlzheimer Disease

Start: 2007-11-30End: 2013-02-28Updated: 2016-01-01